CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

HGF opens its 16th Office: Westport, Ireland.

HGF are continuing to expand, with a strategic move into Ireland and the opening of its 16th office in Westport in the West of Ireland. The office location was chosen to capitalise on investments in the life sciences sector and be in close proximity to Galway, a globally recognised hub for MedTech innovations. The new office will be led by Life Sciences Partner Craig Thomson, who will be supported by a team of Irish qualified patent and trade mark attorneys and the wider pool of talent throughout HGF.
Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients in relation to biotechnological, pharmaceutical, chemical and medtech inventions. As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding and acquisition due diligence, and advising on aggressive/defensive strategies in relation to third party IP.
Craig Thomson, Partner commented. “Having worked in Ireland for almost the last 10 years, I am increasingly impressed by the growth and development of home-grown innovative businesses.  I am delighted to open up access for those businesses to the extensive pool of talent that HGF has to offer”.
Paul Sanderson, CEO commented. “HGF understands the importance of growth in Europe, with Brexit on the horizon. This has been a strategic decision that ensures the firm is well positioned for Brexit and the opportunities and challenges that it will bring to the intellectual property industry, both in Europe and the wider international community. Our continued expansion reflects our commitment to providing the highest quality service both now and in the future.”
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026